1. Will other drugmakers end up with deals like Endo’s $10M opioid settlement? — AstraZeneca Imfinzi combo fails advanced lung cancer study — FDA says they were “lucky” with Novartis data manipulation controversy — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Ship Pending gone by September

Discussion in 'KCI' started by anonymous, Feb 7, 2019 at 7:09 AM.

  1. anonymous

    anonymous Guest

    90% of the SP teams being let go WTF
     
  2. anonymous

    anonymous Guest

    If the Hawk were still here. He would allow this
     
  3. anonymous

    anonymous Guest

    Channel stuffing helps revenue and should increase commission payouts. Place those orders sales team!
     
  4. anonymous

    anonymous Guest

    WTF is the writing has been on the wall for years here. You are for sale, have been and will be
     
  5. anonymous

    anonymous Guest

    Apax-backed business preps possible $5B IPO
    December 13, 2018
    • Share:
    Therapeutic Devices | San Antonio, TX
     
  6. anonymous

    anonymous Guest

    Yeah this company is so fucked up for letting go people who worked for that company for years. Shame on them!!!